Company Overview
Company Type: Public Company
Website: www.acastipharma.com
Number of Employees: 32
Ticker: ACST (NasdaqCM)
Year Founded: 2002


Business Description
Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The companyâ€™s lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.

Financial Information (Currency: CAD, in mm) 
Market Capitalization
33.3
EBITDA
(22.4)
Total Enterprise Value
4.0
TEV/EBITDA
NM
EBIT
(22.3)
Cash & ST Invst.
29.4
P/Diluted EPS Before Extra
NM
Net Income
(57.0)
Total Debt
0.1
Price/Tang BV
1.3x
Capital Expenditure
0.0
Total Assets
99.3
Total Debt/EBITDA
NM




Currency in CAD in mm, LTM as of Jun-30-2023 TEV and Market Cap are calculated using a close price as of Oct-09-2023


Estimates Snapshot (Current Fiscal Year End: Mar-31-2024 | Currency: CAD)
Periodic Estimates
Current FQ
Current FQ+1
Current FY
Current FY+1
NTM
EPS (GAAP)
(0.45)
(0.62)
(2.61)
(2.26)
(2.52)
Revenue (mm)
0.00
0.00
0.00
0.00
0.00

Forward Multiples (Current FY)

Price/Earnings
NM

Non-Periodic Estimates

Recommendation
Outperform (2.00)
Target Price
15.92
Potential Upside
353.86%


Key Professionals
Name
Title
Kohli, Prashant 
Chief Executive Officer
Ford, Brian D.
Interim Chief Financial Officer
MacDonald, R. Loch
Member of Scientific Advisory Board & Chief Medical Officer
D'Andrea, Carrie 
VP of Clinical Operations
Kumar, Amresh 
VP of Program Management

Key Board Members
Name
Title
Kavuru, Vimal Kumar
Independent Chairman
MacDonald, R. Loch
Member of Scientific Advisory Board & Chief Medical Officer
Olds, Donald John
Independent Director
Choi, Alex 
Member of Scientific Advisory Board
Chou, Sherry H-Y
Member of Scientific Advisory Board
Derby, Michael L.
Independent Director
Ducruet, Andrew 
Member of Scientific Advisory Board
Kimberly, W. Taylor
Member of Scientific Advisory Board
Rabinstein, Alejandro A.
Member of Scientific Advisory Board


Primary Industry Classification
Pharmaceuticals


Primary Office Location
3009 boulevard de la Concorde East Suite 102 | Laval, QC | H7E 2B5 | Canada
Phone: 450-687-2262   

Current and Pending Investors
Altamont Phamaceutical Holdings, LLC, Neptune Wellness Solutions Inc. (NasdaqCM:NEPT), Shore Pharma LLC, SS Pharma LLC

Prior Investors
Natcan Investment Management Inc., The Fiera Capital QSSP II Investment Fund Inc.

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 3.51
Market Cap (mm)
33.0
Open
 3.43
Shares Out. (mm)
9.4
Previous Close
 3.51
Float %
70.4%
Change on Day
(0.04)
Shares Sold Short (mm)
0.2
Change % on Day
(1.1)%
Dividend Yield %
-
Day High/Low
 3.63/ 3.41
Diluted EPS Excl. Extra Items
(7.65)
52 wk High/Low
 6.86/ 2.34
P/Diluted EPS Before Extra
NM
Volume (mm)
0.02
Avg 3M Dly Vlm (mm)
0.06
Beta 5Y
1.33


 
Delayed Quote** | Last Updated on Oct-10-2023 12:00 AM (GMT-5)
NasdaqCM:ACST - Common Stock


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Grace Therapeutics, Inc.
Grace Therapeutics, Inc. is a life sciences company developing drug delivery solutions. The company was incorporated in 2014 and is based in East Brunswick, New Jersey.

United States and Canada
Life Sciences Tools and Services
-
-
-
Acasti Pharma U.S., Inc.

United States and Canada
-
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Oct-6-2023
-
Shelf Registration
Target
Acasti Pharma Inc. (NasdaqCM:ACST)

Shore Pharma LLC,SS Pharma LLC
17.01
Sep-24-2023
Sep-25-2023
Private Placement
Target
Acasti Pharma Inc. (NasdaqCM:ACST)
Shore Pharma LLC,SS Pharma LLC

7.50
Aug-25-2023
-
Shelf Registration
Target
Acasti Pharma Inc. (NasdaqCM:ACST)


3.11
Nov-10-2021
-
Public Offering
Target
Acasti Pharma Inc. (NasdaqCM:ACST)


11.05
May-07-2021
Aug-27-2021
Merger/Acquisition
Buyer
Grace Therapeutics, Inc.
Acasti Pharma Inc. (NasdaqCM:ACST)

-
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Oct-10-2023
Annual General Meeting
Acasti Pharma Inc., Annual General Meeting, Oct 10, 2023
Oct-10-2023
Shareholder/Analyst Calls
Acasti Pharma Inc. - Shareholder/Analyst Call
Oct-06-2023
Shelf Registration Filings
Acasti Pharma Inc. has filed a Shelf Registration in the amount of $17.014107 million.
Sep-25-2023
Private Placements
Acasti Pharma Inc. announced that it has received $7.499388 million in funding from SS Pharma LLC, Shore Pharma LLC
Sep-24-2023
Private Placements
Acasti Pharma Inc. announced that it expects to receive $7.499388 million in funding from SS Pharma LLC, Shore Pharma LLC

Competitors
AbbVie Inc. (NYSE:ABBV), Aker BioMarine AS (OB:AKBM), Alkeus Pharmaceuticals, Inc., Amarin Corporation plc (NasdaqGM:AMRN), Amgen Inc. (NasdaqGS:AMGN), Astellas Pharma Inc. (TSE:4503), AstraZeneca PLC (LSE:AZN), Bayer Aktiengesellschaft (XTRA:BAYN), Bioriginal Food & Science Corporation, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company (NYSE:BMY), Cardax, Inc. (OTCPK:CDXI), Eli Lilly and Company (NYSE:LLY), Enzymotec Ltd., Genentech, Inc., Gilead Sciences, Inc. (NasdaqGS:GILD), GSK plc (LSE:GSK), Johnson & Johnson (NYSE:JNJ), Kubota Pharmaceutical Holdings Co., Ltd. (TSE:4596), LES LABORATOIRES SERVIER, SAS, Matinas BioPharma Holdings, Inc. (NYSEAM:MTNB), Merck & Co., Inc. (NYSE:MRK), Mitsubishi Tanabe Pharma Corporation, Novartis AG (SWX:NOVN), Pfizer Inc. (NYSE:PFE), Reata Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN), Sanofi (ENXTPA:SAN), Takeda Pharmaceutical Company Limited (TSE:4502)

M&A Advisors
Oppenheimer & Co. Inc., Osler, Hoskin & Harcourt LLP


Advisors
Most Recent Auditor
Ernst & Young LLP
M&A Advisors
Oppenheimer & Co. Inc., Osler, Hoskin & Harcourt LLP
Private Placement Advisors
Echelon Wealth Partners Inc.
Public Offering Advisors
KPMG LLP, KPMG LLP (Canada), Norton Rose Fulbright Canada LLP, Osler, Hoskin & Harcourt LLP, ROTH Capital Partners, LLC
Key development Advisor
Oppenheimer & Co. Inc.


Most Recent Auditor
Ernst & Young LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
The Economy Matters

Oct 09, 2023 12:08 AM
ACST
The Economy Matters
Reports
8
CFRA Equity Research

Oct 08, 2023 12:04 AM
ACST
Acasti Pharma Inc.
Reports
9
S&P Global Compustat

Oct 05, 2023 04:36 AM
ACST
Acasti Pharma Inc 2023_10_05
Reports
15
ValuEngine, Inc.

Oct 02, 2023 05:54 AM
ACST
ValuEngine Industry Report for Medical-Generic Drugs
Reports
10
ValuEngine, Inc.

Oct 02, 2023 02:43 AM
ACST
ValuEngine Rating and Forecast Report for ACST
Reports
11
Smart Insider Ltd.

Sep 28, 2023 02:06 AM
ACST
Acasti Pharma Inc: 1 director
Reporting Results*
1
GlobalData

Sep 26, 2023 03:12 AM
ACST
Acasti Pharma Inc
Reports
225
GlobalData

Sep 15, 2023 04:03 AM
ACST
Acasti Pharma Inc (ACST.NASD) - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
41
S&P Global Compustat

Sep 07, 2023 03:37 AM
ACST
Acasti Pharma Inc 2023_09_07
Reports
15
GlobalData

Aug 23, 2023 06:44 AM
ACST
Acasti Pharma Inc (ACST.NASD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
54


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Shore Pharma LLC

1,188,076

12.64

4.3

Sep-25-2023


Sambamurty, Iyer Swami

781,592

8.32

2.8

Jul-10-2023


Kottayil, George 

494,698

5.26

1.8

Aug-18-2023


Kavuru R.Ph., Vimal Kumar

124,344

1.32

0.4

Sep-25-2023


Kottayil Grace Pharma LLC

124,344

1.32

0.4

Aug-18-2023


Neugeboren, Edward Alan

37,895

0.40

0.1

Aug-18-2023


Kohli, Prashant 

21,357

0.23

0.1

Aug-18-2023


Renaissance Technologies LLC

11,266

0.12

0.0

Jun-30-2023


Kumar Ph.D., Amresh 

11,119

0.12

0.0

Jul-14-2023


National Bank Investments Inc.

3,069

0.03

0.0

Jun-30-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Shore Pharma LLC
1,188,076
676,371
Kottayil, George 
494,698
472,622
Kavuru R.Ph., Vimal Kumar
124,344
124,344
Neugeboren, Edward Alan
37,895
37,895
Kumar Ph.D., Amresh 
11,119
11,119

Top Sellers
Sellers
Common Stock Equivalent Held
Change
D'Alvise, Janelle 
1,094
(156,234)
Renaissance Technologies LLC
11,266
(3,862)
Virtu Financial LLC, Asset Management Arm
0
(3,709)
UBS Asset Management AG
0
(624)
JPMorgan Chase & Co, Brokerage and Securities Investments
0
(208)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
CaPre, EPANOVA (Future), GTX-101 (Future), GTX-102 (Future), GTX-104 (Future), ONEMIA, VASCEPA (Future)


Upcoming Events
Date/Time
Type
Oct-11-2023
Special Calls
Nov-10-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Oct-06-2023
-
Acasti Pharma Inc. (NasdaqCM:ACST)
SEC
S-3
1 MB
Sep-26-2023
-
Acasti Pharma Inc. (NasdaqCM:ACST)
SEDAR
News Releases
185 KB
Sep-26-2023
-
Acasti Pharma Inc. (NasdaqCM:ACST)
SEDAR
News Releases
185 KB
Sep-26-2023
Sep-24-2023
Acasti Pharma Inc. (NasdaqCM:ACST)
SEC
8-K (1.01, 3.02, 8.01, 9.01)
1 MB
Aug-25-2023
-
Acasti Pharma Inc. (NasdaqCM:ACST)
SEDAR
Management Proxy Materials
145 KB
Aug-25-2023
-
Acasti Pharma Inc. (NasdaqCM:ACST)
SEDAR
Management Proxy Materials
395 KB
Aug-25-2023
-
Acasti Pharma Inc. (NasdaqCM:ACST)
SEDAR
Management Proxy Materials
238 KB
Aug-25-2023
-
Acasti Pharma Inc. (NasdaqCM:ACST)
SEDAR
Management Proxy Materials
105 KB
Aug-25-2023
-
Acasti Pharma Inc. (NasdaqCM:ACST)
SEC
S-8
260 KB
Aug-25-2023
-
Acasti Pharma Inc. (NasdaqCM:ACST)
SEC
DEFA14A
2 MB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Kavuru R.Ph., Vimal Kumar (Independent Chairman)
Sep-25-2023
Class A Shares
676,371
1,699,035
Open Market Acquisition
(122.52)
Form 4
Shore Pharma LLC
Sep-25-2023
Class A Shares
676,371
1,699,127
Private Acquisition
132.18
Multiple
Olds M.Sc., MBA, Donald John (Independent Director)
Aug-31-2023
Class A Shares
381
1,062
Open Market Acquisition
48.11
Form 4
Boily, Jean-FranÃ§ois  (Former Vice President of Finance)
Sep-26-2019
Class A Shares
220
29,539
Open Market Acquisition
New
Exchange Announcement
Canan CPA, CPA, Jean-Marie  (Former Independent Director)
Aug-19-2019
Class A Shares
208
25,680
Open Market Acquisition
9.30
Exchange Announcement
-
Aug-19-2019
Class A Shares
175
21,580
Open Market Acquisition
-
Exchange Announcement
-
Aug-19-2019
Class A Shares
33
4,100
Open Market Acquisition
-
Exchange Announcement
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Kavuru, Vimal Kumar
Independent Chairman
450-687-2262
-

MacDonald, R. Loch
Member of Scientific Advisory Board & Chief Medical Officer
450-687-2262
-

Olds, Donald John
Independent Director
450-687-2262
-

Choi, Alex 
Member of Scientific Advisory Board
450-687-2262
-

Chou, Sherry H-Y
Member of Scientific Advisory Board
450-687-2262
-

Derby, Michael L.
Independent Director
450-687-2262
-

Ducruet, Andrew 
Member of Scientific Advisory Board
450-687-2262
-

Kimberly, W. Taylor
Member of Scientific Advisory Board
450-687-2262
-

Rabinstein, Alejandro A.
Member of Scientific Advisory Board
450-687-2262
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Kohli, Prashant 
Chief Executive Officer
450-687-2262
-

Ford, Brian D.
Interim Chief Financial Officer
450-687-2262
-

MacDonald, R. Loch
Member of Scientific Advisory Board & Chief Medical Officer
450-687-2262
-

D'Andrea, Carrie 
VP of Clinical Operations
450-687-2262
-

Kumar, Amresh 
VP of Program Management
450-687-2262
-

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENTâ€™S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligenceâ€™s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
